Elixir Pharmaceuticals Inc.

Lenny Guarente, PhD, in a molecular genetics laboratory at the Massachusetts Institute of Technology, has found single gene mutations that appear to double the life span of single-celled yeast. Cynthia Kenyon, PhD, a biochemist with the University of California, has found a similar gene that appears to contribute to long life in roundworms. Elixir Pharmaceuticals Inc. was founded to apply the research of Guarente and Kenyon to that higher-order, two-legged mammal known as man.

Slow and steady wins the race. The fabled tortoise not only demonstrates the virtue of persistence but may also hold the secrets of longevity. Tortoises can live a hundred years and more, and it seems that they do this by growing and aging at a very slow rate. Lower animals have much to teach us as well. Lenny Guarente, PhD, in a molecular genetics laboratory at the Massachusetts Institute of Technology , has found single gene mutations that appear to double the life span of single-celled yeast. Cynthia Kenyon, PhD, a biochemist with the University of California , has confirmed that finding in roundworms, in which a similar gene appears to contribute to long life. The same gene seems to also increase the likelihood that worms will lapse into a dormant state that permits them to live for months without food.

The discovery that a single gene that appears to control aging has been conserved from yeast to a higher animal has generated hope and excitement that a similar gene will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

In partnership with

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development